Is it safe for an adult to take 15 mg of melatonin?

Is 15 mg of Melatonin Safe for Adults?

While 15 mg of melatonin is not associated with serious adverse events and appears physically safe in the short term, this dose is not recommended for insomnia treatment and substantially exceeds evidence-based dosing. The American Academy of Sleep Medicine explicitly recommends against using melatonin for chronic insomnia treatment, even at the 2 mg dose studied in clinical trials 1.

Safety Profile at Higher Doses

The available evidence suggests melatonin has a favorable safety profile even at doses ≥10 mg:

• A systematic review of high-dose melatonin studies (≥10 mg) found no detectable increase in serious adverse events or withdrawals due to adverse effects, though it did increase minor side effects like drowsiness, headache, and dizziness 2
• Most reported adverse events are mild to moderate: daytime sleepiness (1.66%), headache (0.74%), dizziness (0.74%) 3
• Studies examining doses up to 12 mg for up to 29 weeks found melatonin to be generally well-tolerated 3
• Recent trials using 15 mg preoperatively showed no adverse events and good tolerability 4, 5

Important Safety Caveats

However, several critical concerns exist:

• Cardiac rhythm disturbances: Case reports describe atrioventricular block and ventricular arrhythmia associated with 10 mg daily melatonin, with complete resolution after discontinuation 6
• Limited long-term data: Most safety studies are short-term (≤4 weeks), with insufficient evidence for continuous therapy over extended periods 2, 3
• Quality control issues: Over-the-counter melatonin preparations show substantial variability in actual content, making dosing unreliable 7

Why 15 mg Is Not Recommended

Lack of Efficacy Evidence

The dose is problematic for several reasons beyond safety:

• No clinical trials support 15 mg for insomnia: The AASM guideline reviewed trials using 2 mg doses and found insufficient benefit to recommend melatonin for sleep onset or maintenance insomnia 1
• Melatonin functions as a chronobiotic, not a hypnotic: Its primary mechanism involves circadian phase shifting, not direct sleep induction—timing matters more than dose 7
• Supraphysiological dosing is normalized without evidence: Physiological nighttime melatonin levels are achieved with 0.3-1 mg; doses of 15 mg far exceed this without demonstrated additional benefit 7

Appropriate Melatonin Use

If melatonin is to be used despite guideline recommendations:

• Circadian rhythm disorders (delayed sleep-wake phase disorder, shift work disorder, jet lag) represent the most appropriate indication
• Dosing should be 0.5-5 mg, with most evidence supporting 2-3 mg
• Timing is critical: Administration should occur 2-3 hours before desired sleep time for phase advancement, not reflexively at bedtime
• Duration: Use should be time-limited with reassessment of need

Better Alternatives for Insomnia

The AASM guideline provides weak recommendations FOR the following agents over melatonin 1:

For sleep onset insomnia:

• Zolpidem 10 mg
• Zaleplon 10 mg
• Triazolam 0.25 mg
• Ramelteon 8 mg (melatonin receptor agonist)

For sleep maintenance insomnia:

• Zolpidem 10 mg
• Temazepam 15 mg
• Doxepin 3-6 mg
• Suvorexant 10-20 mg

Common Pitfalls to Avoid

1. Misdiagnosing circadian disorders as primary insomnia: A patient with delayed sleep-wake phase disorder will not respond to hypnotics but may benefit from properly timed melatonin
2. Using bedtime dosing reflexively: This timing is often incorrect for circadian phase shifting
3. Assuming "natural" means safe and effective: Melatonin requires the same diagnostic rigor as prescription sleep medications 7
4. Continuing ineffective treatment: If no benefit occurs within 1-2 weeks, reassess the diagnosis rather than increasing the dose

Bottom Line

Taking 15 mg of melatonin is unlikely to cause serious harm in most adults, but it represents inappropriate dosing without supporting evidence and should not be used for routine insomnia treatment. If sleep difficulties persist, evaluation for underlying circadian rhythm disorders, sleep apnea, or other conditions is warranted, with consideration of evidence-based pharmacologic options if behavioral interventions fail.